By Nana O 
A groundbreaking study spearheaded by researchers at NYU Langone Health and its Perlmutter Cancer Center has unveiled a highly promising method for predicting the recurrence of stage III melanoma, the most aggressive form of skin cancer. By monitoring blood levels of circulating tumor DNA (ctDNA) – fragments of genetic material shed by dying tumor cells – clinicians may soon possess a powerful new tool to identify patients at high risk of their disease returning, enabling more personalized and potentially life-saving treatment strategies.
Early Detection: A Critical Need in Stage III Melanoma
The findings, published online on April 15th in the esteemed journal The Lancet Oncology, represent the most extensive assessment to date of ctDNA’s predictive capabilities in stage III melanoma patients. This stage of melanoma is characterized by the spread of tumor cells from the primary skin site to nearby lymph nodes. Following surgical removal of these affected lymph nodes, detecting residual disease or the earliest signs of recurrence can be exceptionally challenging with conventional imaging techniques such as X-rays and CT scans. This diagnostic gap has long fueled the urgent search for more sensitive and reliable methods to track cancer activity and treatment response.
The study’s lead author, Mahrukh Syeda, MS, a research scientist in the Ronald O. Perlmutter Department of Dermatology at NYU Grossman School of Medicine, emphasized the significance of these findings. "Our findings suggest that circulating tumor DNA tests could help oncologists identify which melanoma patients are most likely to respond well to therapy," Syeda stated. "In the future, such assessments may be used routinely in the clinic to help guide treatment decisions."
Key Findings: ctDNA as a Potent Predictor of Recurrence
The research team analyzed blood samples from nearly 600 men and women who had previously participated in a clinical trial for stage III melanoma. These participants were drawn from diverse geographical locations, including Europe, North America, and Australia, lending significant weight and generalizability to the study’s conclusions. The ctDNA levels were meticulously compared against clinical evidence of cancer recurrence, with sophisticated statistical analyses accounting for various factors that could influence disease progression, such as patient sex, age, and the specific therapy regimen received.
One of the most striking revelations from the study was that approximately 80% of stage III melanoma patients who had detectable levels of ctDNA before commencing treatment to suppress their tumors subsequently experienced a recurrence. This pre-treatment detection of ctDNA emerged as a robust indicator of a heightened risk for disease re-emergence.
Furthermore, the study unearthed a critical correlation between the presence and quantity of ctDNA and the speed of recurrence. Patients with detectable ctDNA experienced disease return more than four times faster than those whose tests showed no detectable levels of this biomarker. The higher the concentration of ctDNA detected, the more rapid the cancer’s return. This dose-response relationship underscores the dynamic nature of ctDNA as a real-time indicator of disease burden.
Monitoring Treatment Progress: A Paradigm Shift in Patient Management
Beyond pre-treatment assessment, the study also highlighted the utility of ctDNA monitoring during treatment. The researchers observed that nearly all patients who exhibited detectable ctDNA levels at three, six, nine, or twelve months into their therapeutic course ultimately experienced melanoma recurrence. This suggests that the persistence or reappearance of ctDNA during treatment, even if not initially present, could signal that the disease is not being adequately controlled or is actively worsening.
"Unlike standard, tissue-based analyses of tumor cells, which can only suggest the likelihood of recurrence, circulating tumor DNA tests provide a clear, direct measure of the disease itself and can tell us outright that melanoma has returned," explained study senior author David Polsky, MD, PhD, a dermatologist and the Alfred W. Kopf, M.D., Professor of Dermatologic Oncology at NYU Langone Health. "Early feedback from a ctDNA analysis might save lives," he added, recognizing the aggressive nature of melanoma once it has spread.
The Science Behind ctDNA Detection
The ctDNA method operates by targeting the most common genetic mutations found within melanoma cells. As these tumor cells break down and die, they release fragments of their DNA into the surrounding bloodstream. These circulating fragments, carrying the tell-tale mutations, can then be detected and quantified through advanced molecular techniques. This non-invasive approach offers a significant advantage over traditional biopsies, which are invasive and only provide a snapshot of the tumor at a specific point in time.
Broader Context and Prior Research
The utility of ctDNA in cancer detection and monitoring is not entirely novel. Previous research has demonstrated its efficacy in tracking the progression of other cancers, including colorectal and breast cancers. In a significant prior study, published in 2021, the same research team found that elevated ctDNA levels in patients with stage IV melanoma – cancer that has metastasized throughout the body – were associated with poorer survival outcomes. They also established that changes in ctDNA measurements during treatment could be utilized to stratify patients based on their likelihood of survival.
This latest investigation builds upon that foundational work by focusing specifically on stage III melanoma, a critical juncture where early intervention can profoundly impact long-term prognosis. The scale of this study, involving nearly 600 participants, solidifies ctDNA’s role as a robust prognostic biomarker in this patient population.
Comparative Efficacy: Outperforming Traditional Methods
A particularly compelling finding from the study is that assessing ctDNA levels proved to be as effective, and in some instances superior, to other experimental tests that examine the tumor tissue itself. These comparative tests include those that measure immune activity within cancer cell clusters. The direct measurement of tumor-derived DNA in the bloodstream offers a more immediate and unambiguous reflection of the disease’s presence and activity.
Future Directions and Limitations
Despite the overwhelmingly positive results, the researchers acknowledge that the ctDNA test is not infallible. Dr. Polsky cautioned that in a minority of cases, cancer recurrence still occurred even when patients initially presented with a negative ctDNA test prior to therapy. This highlights the ongoing need for refinement and improvement in the sensitivity of these tests.
To address this, the team plans to focus on enhancing the test’s sensitivity in future research. Moreover, a crucial next step will involve conducting clinical trials to rigorously evaluate whether using ctDNA-based biomarker information to guide treatment decisions can demonstrably improve patient survival rates and overall quality of life. This transition from prognostic assessment to therapeutic guidance is a critical frontier in precision oncology.
Funding and Collaborations
The research received substantial funding support from Novartis Pharmaceuticals Corporation.
The study involved a broad international collaboration, underscoring the global effort to combat melanoma. Key investigators included Jennifer Wiggins-Crosby, PhD, and Saim Ali, BA, from NYU Langone Health; Georgina Long, MD, PhD, from the University of Sydney, Australia; James Garrett, PhD, from Novartis Pharmaceuticals Corporation, Cambridge, Massachusetts; Victoria Atkinson, MD, from the University of Queensland, Australia; Mario Santinami, MD, from the National Cancer Institute of Milan, Italy; Dirk Schadendorf, MD, from the University of Duisburg-Essen, Germany; Axel Hauschild, MD, from the University Hospital, Campus Kiel, Germany; Michael Millward, MD, from the University of Western Australia, Nedlands; Mario Mandala, MD, from the University of Perugia, Italy; Vanna Chiarion-Sileni, MD, from the Veneto Institute of Oncology, Padua, Italy; Michael Smylie, MD, from the Cross Cancer Institute, Edmonton, Canada; Georgy Manikhas, MD, from St. Petersburg Oncology Hospital, Russia; Reinhard Dummer, MD, from the University Hospital Zurich Skin Cancer Center, Switzerland; Sachin Bajirao Adnaik, PhD, from Novartis Healthcare Pvt. Ltd., Hyderabad, India; and Monique Tan, MD, MPH, and Maya Dajee, PhD, from Novartis Pharmaceuticals, East Hanover, New Jersey.
Dr. Polsky’s disclosures include advisory board memberships for Novartis and Merck, honoraria from WebMD, Physicians’ Education Resource, and Oncology Specialty Group (OncLive), and laboratory research contracts from Novartis and Bristol-Myers Squibb, as well as laboratory support from Bio-Rad. These relationships are managed in accordance with NYU Langone Health’s policies.
Implications for the Future of Melanoma Treatment
The integration of ctDNA monitoring into routine clinical practice for stage III melanoma patients could herald a new era of personalized cancer care. By providing early, accurate, and actionable insights into a patient’s risk of recurrence, clinicians can better tailor adjuvant therapies, potentially sparing patients unnecessary treatments or, conversely, intensifying treatment for those most at risk. This precision approach promises to optimize outcomes, improve survival rates, and enhance the quality of life for individuals battling this formidable disease. The ongoing research and clinical implementation of ctDNA testing represent a significant leap forward in the fight against skin cancer.